Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Journal Articles

Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia

Enes Dasdemir, Ivo Veletic, Christopher P. Ly, Andres E Quesada, Fatima Z Jelloul, Pamella Borges, Sreyashi Basu, Sonali Jindal, Zhiqiang Wang, Alexander J Lazar, Khalida M Wani, Dinler A Antunes, Patrick K. Reville, Preethi Gunaratne, Robert J Tower, Padmanee Sharma, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 1059.

https://doi.org/10.1182/blood-2024-201932

Published: 2024

Journal Articles

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Blood (2024) 144 (Supplement 1): 735.

https://doi.org/10.1182/blood-2024-203706

Published: 2024

Journal Articles

Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission

Eitan Kugler, Hagop M. Kantarjian, Alexandre Bazinet, Wei-Ying Jen, Naval Daver, Courtney D. DiNardo, Nicholas J. Short, Jayastu Senapati, Gautam Borthakur, Naveen Pemmaraju, Ghayas C. Issa, Alex Bataller, Patrick K. Reville, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 2861.

https://doi.org/10.1182/blood-2024-199903

Published: 2024

Journal Articles

Atezolizumab Combined with Venetoclax and Obinutuzumab for Frontline CLL

Patrick K. Reville, Sogand Sajedi, Alessandra Ferrajoli, Jan A. Burger, Michael J. Keating, Naveen Garg, Qing Deng, Michael R. Green, Hussein A. Abbas, William G. Wierda, Nitin Jain

Blood (2024) 144 (Supplement 1): 1014.

https://doi.org/10.1182/blood-2024-206306

Published: 2024

Journal Articles

Safety and Efficacy of a Novel Mammalian-Derived Asparaginase without Glutaminase Activity in Combination with Venetoclax for Acute Myeloid Leukemia

Dhabya Majid, Zhe WANG, Bin Yuan, Mhd Yousuf Yassouf, Amanda Schalk, Basant T. Gamal, Qi Zhang Tatarata, Jessica Lynn Root, Araceli Isabella Garza, Annie Hoai Nguyen, Sammy Ferri-Borgogno, Patrick K. Reville, Arnon Lavie, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 2777.

https://doi.org/10.1182/blood-2024-203584

Published: 2024

Journal Articles

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

Blood (2024) 144 (Supplement 1): 219.

https://doi.org/10.1182/blood-2024-200393

Published: 2024

Journal Articles

ICASA: An Interactive Comprehensive Atlas of Single Cells in AML from 82 Bone Marrow Samples

Bofei Wang, Poonam N Desai, Jae Jun Ku, Naval Daver, Patrick K. Reville, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 2213.

https://doi.org/10.1182/blood-2024-202595

Published: 2024

Journal Articles

Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker

Hussein A. Abbas, Bofei Wang, Jennifer Marvin-Peek, Bin Yuan, Araceli Isabella Garza, Jessica Lynn Root, Andrea Arruda, Yiwei Liu, Courtney D. DiNardo, Tapan M. Kadia, Naval Daver, Philip L Lorenzi, Koji Sasaki, Steven M. Kornblau, Mark D. Minden, Farhad Ravandi, Hagop M. Kantarjian, Patrick K. Reville

Blood (2024) 144 (Supplement 1): 2912.

https://doi.org/10.1182/blood-2024-201725

Published: 2024

Journal Articles

Single Cell Profiling of Ph-Positive Acute Lymphoblastic Leukemias Reveals Distinct Cells of Origin

Sogand Sajedi, Nicholas J. Short, Enes Dasdemir, Bofei Wang, Cedric Nasnas, Elias Jabbour, Hagop M. Kantarjian, Patrick K. Reville, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 4219.

https://doi.org/10.1182/blood-2024-210997

Published: 2024

Journal Articles

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2024-211454

Published: 2024

Journal Articles

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH -Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials

Blood (2024) 144 (Supplement 1): 2883.

https://doi.org/10.1182/blood-2024-200387

Published: 2024

Journal Articles

Multimodal Spatial Profiling in Acute Myeloid Leukemia

Christopher P. Ly, Ivo Veletic, Christopher D. Pacheco, Enes Dasdemir, Fatima Z Jelloul, Sammy Ferri-Borgogno, Akshay Basi, Javier A. Gomez, Jessica Lynn Root, Patrick K. Reville, Andres E Quesada, Carlos E. Bueso-Ramos, Miriam B. Garcia, Jared K. Burks, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 2681.

https://doi.org/10.1182/blood-2024-203816

Published: 2024

Journal Articles

Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis

Ivo Veletic, Taghi Manshouri, C. Cameron Yin, Christopher D. Pacheco, Christopher P. Ly, Enes Dasdemir, Evan N. Cohen, Lucia Masarova, Naveen Pemmaraju, Prithviraj Bose, Hagop M. Kantarjian, Zeev Estrov, Patrick K. Reville, Andrew Dunbar, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 1760.

https://doi.org/10.1182/blood-2024-211966

Published: 2024

Journal Articles

Comprehensive Characterization of Inflammatory Cytokines in Chronic Lymphocytic Leukemia Highlight Immune Dysregulation and Associates with MRD

Bofei Wang, Jessica Lynn Root, Araceli Isabella Garza, Joyce Breaker, William G. Wierda, Hussein A. Abbas, Patrick K. Reville

Blood (2024) 144 (Supplement 1): 3236.

https://doi.org/10.1182/blood-2024-200843

Published: 2024

Journal Articles

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Blood (2024) 143 (20): 2059–2072.

https://doi.org/10.1182/blood.2023022832

Published: 2024

Includes: Supplemental data

Journal Articles

Single-Cell Characterization of TP53-Mutated AML Patients Treated with Frontline Azacitidine, Venetoclax, and Magrolimab Reveals Mechanisms of Response and Resistance

Poonam N Desai, Bofei Wang, Patrick K Reville, Fatima Z Jelloul, Pamella Borges, Jayastu Senapati, Micah Castillo, Preethi Gunaratne, Naveen Pemmaraju, Tapan M. Kadia, Farhad Ravandi, Guillermo Garcia-Manero, Naval Daver, Hussein A Abbas

Blood (2023) 142 (Supplement 1): 64.

https://doi.org/10.1182/blood-2023-187307

Published: 2023

Journal Articles

Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens

Naszrin Arani, Emmanuel Almanza, Alex Bataller, Courtney D. DiNardo, Farhad Ravandi, Naval Daver, Naveen Pemmaraju, Musa Yilmaz, Abhishek Maiti, Patrick K Reville, Sanam Loghavi, Hussein A Abbas, Guillermo Garcia-Manero, Nicholas J. Short, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4236.

https://doi.org/10.1182/blood-2023-191181

Published: 2023

Journal Articles

Novel Agents with Efficacy Against Cellular Models of Familial Platelet Disorder with Myeloid Malignancy (FPD-MM) Associated with Germline Mutant RUNX1

Christopher Peter Mill, Warren C. Fiskus, Courtney D. DiNardo, Patrick K Reville, John Davis, Christine Birdwell, Kaberi Das, Hanxi Hou, Koichi Takahashi, Sanam Loghavi, Joseph D. Khoury, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 2765.

https://doi.org/10.1182/blood-2023-190655

Published: 2023

Journal Articles

Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis

Jayastu Senapati, Sanam Loghavi, Patrick K Reville, Naval Daver, Gautam Borthakur, Courtney D. DiNardo, Elias Jabbour, Nicholas J. Short, Naveen Pemmaraju, Abhishek Maiti, Ghayas C. Issa, Uday R. Popat, Amin Alousi, Elizabeth J. Shpall, Koji Sasaki, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2023-179380

Published: 2023

NARROW

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission

Atezolizumab Combined with Venetoclax and Obinutuzumab for Frontline CLL

Safety and Efficacy of a Novel Mammalian-Derived Asparaginase without Glutaminase Activity in Combination with Venetoclax for Acute Myeloid Leukemia

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

ICASA: An Interactive Comprehensive Atlas of Single Cells in AML from 82 Bone Marrow Samples

Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker

Single Cell Profiling of Ph-Positive Acute Lymphoblastic Leukemias Reveals Distinct Cells of Origin

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH -Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials

Multimodal Spatial Profiling in Acute Myeloid Leukemia

Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis

Comprehensive Characterization of Inflammatory Cytokines in Chronic Lymphocytic Leukemia Highlight Immune Dysregulation and Associates with MRD

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Single-Cell Characterization of TP53-Mutated AML Patients Treated with Frontline Azacitidine, Venetoclax, and Magrolimab Reveals Mechanisms of Response and Resistance

Patterns of Relapse in Patients with Acute Myeloid Leukemia (AML) Treated with Venetoclax-Containing Regimens

Novel Agents with Efficacy Against Cellular Models of Familial Platelet Disorder with Myeloid Malignancy (FPD-MM) Associated with Germline Mutant RUNX1

Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only